| Market Capitalization (Millions $) |
8,615 |
| Shares
Outstanding (Millions) |
67 |
| Employees |
582 |
| Revenues (TTM) (Millions $) |
562 |
| Net Income (TTM) (Millions $) |
-156 |
| Cash Flow (TTM) (Millions $) |
10 |
| Capital Exp. (TTM) (Millions $) |
5 |
Business Description
Blueprint Medicines Corporation is a biopharmaceutical company that specializes in developing precision therapies for patients with genetically defined diseases. The company was founded in 2011 and is headquartered in Cambridge, Massachusetts. Blueprint Medicines focuses on developing small molecule drugs that target specific genetic abnormalities or pathways associated with diseases.
The company's main area of focus is targeted oncology, with a particular emphasis on developing therapies for patients with gastrointestinal stromal tumors (GIST) and other solid tumor types. Blueprint's lead product, Ayvakit (avapritinib), is a small molecule kinase inhibitor that has been approved by the US FDA for the treatment of patients with GIST who have a specific mutation called PDGFRA exon 18.
Blueprint Medicines has several other programs in development, including BLU-285, a potent inhibitor of KIT and PDGFRA kinase mutations that are resistant to current therapies. The company is also developing an investigational drug, BLU-667, which targets RET, a genetic driver of non-small cell lung cancer and thyroid cancer.
In addition to oncology, Blueprint Medicines is also developing therapies for patients with rare genetic diseases including fibrodysplasia ossificans progressiva (FOP) and achondroplasia, which are both caused by specific genetic mutations.
Notably, Blueprint Medicines has established partnerships with other biopharmaceutical companies, including Roche and CStone Pharmaceuticals, for the development and commercialization of its investigational drug candidates.
Overall, Blueprint Medicines Corporation is a leading biopharmaceutical company that is dedicated to developing precision medicines for patients with genetically defined diseases. Through its innovative approach to drug discovery and development, Blueprint Medicines has the potential to transform the lives of patients living with cancer and rare genetic diseases.
Company Address: 45 Sidney Street Cambridge 2139 MA
Company Phone Number: 374-7580 Stock Exchange / Ticker: NASDAQ BPMC
|
11.81% 
100 %